The randomized controlled trial

Nephron - Clinical Practice

Volumn 113, Issue 4, 2009, Pages

  Stel, Vianda S ^a   Zoccali, Carmine ^c   Dekker, Friedo W ^a,b   Jager, Kitty J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

Epidemiology; Patient selection; Randomized controlled trials; Study design

Indexed keywords

CLINICAL TRIAL; DATA ANALYSIS; GOLD STANDARD; HUMAN; PATIENT PARTICIPATION; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAMPLE SIZE;

DATA INTERPRETATION, STATISTICAL; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 70049107182     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000237143     Document Type: Review

References (26)

1. Stel VS, Jager KJ, Zoccali C, Wanner C, Dekker FW: The randomized clinical trial: An unbeatable standard in clinical research? Kidney Int 2007; 72: 539-542.
2. Jager KJ, Stel VS, Wanner C, Zoccali C, Dekker FW: The valuable contribution of observational studies to nephrology. Kidney Int 2007; 72: 671-675.
3. Strippoli GF, Craig JC, Schena FP: The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 2004; 15: 411-419.
4. Zoccali C, Abramowicz D, Cannata-Andia JB, Cochat P, Covic A, Eckardt KU, Fouque D, Heimburger O, McLeod A, Lindley E, Locatelli F, Spasovski G, Tattersall J, Van Biesen W, Wanner C, Vanholder R: European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrol Dial Transplant 2008; 23: 2162-2166.
5. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
6. Greene T, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, Levin NW, Schulman G, Eknoyan G: Design and statistical issues of the hemodialysis (HEMO) study. Control Clin Trials 2000; 21: 502-525.
7. Sullivan C, Sayre SS, Leon JB, Machekano R, Love TE, Porter D, Marbury M, Sehgal AR: Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: A randomized controlled trial. JAMA 2009; 301: 629-635.
8. Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, van Kasterop-Kutz M, van der Heide JJ, Squifflet JP, van Heurn E, Kirste GR, Rahmel A, Leuvenink HG, Paul A, Pirenne J, Ploeg RJ: Machine perfusion or cold storage in deceaseddonor kidney transplantation. N Engl J Med 2009; 360: 7-19.
9. Wang D, Bakhai A: Clinical Trials. A Practical Guide to Design, Analysis and Reporting. London, Remedica, 2006.
10. Torgerson DJ, Roberts C: Understanding controlled trials. Randomisation methods: Concealment. BMJ 1999; 319: 375-376.
11. DePaul V, Moreland J, Eager T, Clase CM: The effectiveness of aerobic and muscle strength training in patients receiving hemodialysis and EPO: A randomized controlled trial. Am J Kidney Dis 2002; 40: 1219-1229.
12. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G: Bloodpressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet 2005; 365: 939-946.
13. Maione A, Nicolucci A, Craig JC, Tognoni G, Moschetta A, Palasciano G, Pugliese G, Procaccini DA, Gesualdo L, Pellegrini F, Strippoli GF: Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial. J Nephrol 2007; 20: 646-655.
14. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D: Improving the reporting of pragmatic trials: An extension of the CONSORT statement. BMJ 2008; 337:a2390.
15. Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P: Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324.
16. Altman DG: Practical Statistics for Medical Research. New York, Chapman & Hall/CRC, 1991.
17. Port FK: Role of observational studies versus clinical trials in ESRD research. Kidney Int 2000; 57:S3-S6.
18. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556.
19. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863.
20. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
21. Vandenbroucke JP: When are observational studies as credible as randomised trials? Lancet 2004; 363: 1728-1731.
22. Covic A, Gusbeth-Tatomir P, Goldsmith D: Negative outcome studies in end-stage renal disease: How dark are the storm clouds? Nephrol Dial Transplant 2008; 23: 56-61.
23. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996; 276: 637-639.
24. Moher D, Schulz KF, Altman D: The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285: 1987-1991. (Pubitemid 32366951)
25. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
26. Greene T: Randomized and observational studies in nephrology: How strong is the evidence? Am J Kidney Dis 2009; 53: 377-388.